{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:41:15Z","timestamp":1780540875198,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1053\/j.seminoncol.2016.02.008","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T07:15:54Z","timestamp":1455002154000},"page":"251-259","source":"Crossref","is-referenced-by-count":29,"title":["Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"43","author":[{"given":"Kami","family":"Maddocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.02.008_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4899-0987-9_24","article-title":"X-linked agammaglobulinemia and Bruton\u2019s tyrosine kinase","volume":"365","author":"Tsukada","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton\u2019s tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.02.008_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11882-001-0065-8","article-title":"The clinical spectrum of Bruton\u2019s agammaglobulinemia","volume":"1","author":"Stewart","year":"2001","journal-title":"Curr Allergy Asthma Rep"},{"issue":"43","key":"10.1053\/j.seminoncol.2016.02.008_bib6","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.1074\/jbc.274.43.30644","article-title":"Syk and Bruton\u2019s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt","volume":"274","author":"Craxton","year":"1999","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1053\/j.seminoncol.2016.02.008_bib7","article-title":"A conditional form of Bruton\u2019s tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC gamma 2 in B cells","volume":"2","author":"Tomlinson","year":"2001","journal-title":"BMC Immunol"},{"issue":"10","key":"10.1053\/j.seminoncol.2016.02.008_bib8","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton\u2019s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J Exp Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.02.008_bib9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.M009137200","article-title":"Phospholipase C-gamma 2 couples Bruton\u2019s tyrosine kinase to the NF kappaB signaling pathway in B lymphocytes","volume":"276","author":"Petro","year":"2001","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1053\/j.seminoncol.2016.02.008_bib10","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib11","doi-asserted-by":"crossref","unstructured":"Ponader S, Chen SS, JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chroniclymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119(5):1182-11899.","DOI":"10.1182\/blood-2011-10-386417"},{"issue":"10","key":"10.1053\/j.seminoncol.2016.02.008_bib12","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinaseCdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminoncol.2016.02.008_bib13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib14","doi-asserted-by":"crossref","unstructured":"Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. Jan 13;117(2):591-594.","DOI":"10.1182\/blood-2010-03-275305"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib15","doi-asserted-by":"crossref","unstructured":"Bernal A, Pastore RD, ASgary Z, et al. Survival of leukemia B cells promoted by engagement of the antigen receptor. Blood 2001;98(10):3050\u20137.","DOI":"10.1182\/blood.V98.10.3050"},{"issue":"2","key":"10.1053\/j.seminoncol.2016.02.008_bib16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2011-12-397158","article-title":"The degree of BCR and DFAT activation predicts clinical outcomes in chronic lymphocytic leukemia","volume":"120","author":"LeRoy","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib17","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminoncol.2016.02.008_bib18","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminoncol.2016.02.008_bib19","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 enhances B-cell receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminoncol.2016.02.008_bib20","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","article-title":"ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"107","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","article-title":"Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology\/the Education Program of the American Society of Hematology","author":"Burger","year":"2011","journal-title":"American Society of Hematology"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib22","first-page":"1","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"122","author":"Herman","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminoncol.2016.02.008_bib23","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"Rooij","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminoncol.2016.02.008_bib24","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2014-02-554220","article-title":"Kinetics of chronic lymphocytic leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib","volume":"123","author":"Wodarz","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminoncol.2016.02.008_bib25","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristic and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.02.008_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"Chem Med Chem"},{"issue":"2","key":"10.1053\/j.seminoncol.2016.02.008_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"29","key":"10.1053\/j.seminoncol.2016.02.008_bib28","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1053\/j.seminoncol.2016.02.008_bib29","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminoncol.2016.02.008_bib30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.02.008_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant toxicity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.02.008_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib33","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: an open-label, multicenter, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib34","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.02.008_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Saftey and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukemia: a single-arm phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5s","key":"10.1053\/j.seminoncol.2016.02.008_bib38","article-title":"A phase 1b\/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","volume":"32","author":"Jaglowski","year":"2014","journal-title":"J Clin Oncol (ASCO Annual Meeting Abstracts)"},{"issue":"19","key":"10.1053\/j.seminoncol.2016.02.008_bib39","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibruitnib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminoncol.2016.02.008_bib40","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib41","first-page":"21","article-title":"Polliack, et al. Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-na\u00efve CLL\/SLL (RESONATE-2, PCYC-1115-CA)","volume":"suppl","author":"Burger","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.02.008_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/fon.14.119","article-title":"The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed\/refractory chronic lymphocytic leukemia","volume":"11","author":"Hallek","year":"2015","journal-title":"Future Oncol"},{"issue":"24","key":"10.1053\/j.seminoncol.2016.02.008_bib43","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminoncol.2016.02.008_bib44","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.02.008_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2016.02.008_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib47","doi-asserted-by":"crossref","unstructured":"Brown JR, Wael AH, Sharman J. et al. Phase 1 study of single agent CC-292, a highly selective Bruton\u2019s tyrosine kinase (Btk) inhibitor, in relasped\/refracotry chronic lymphocytic leukemia (CLL). Blood 2013;122(21):1630.","DOI":"10.1182\/blood.V122.21.1630.1630"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib48","first-page":"29","article-title":"B cell recepted pathway in chronic lymphocytic leukemia: specific role of CC-292","volume":"3","year":"2014","journal-title":"Immunotargets Ther"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2016.02.008_bib49","first-page":"abstr 8553","volume":"32","author":"Fegan","year":"2014","journal-title":"The Bruton\u2019s tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL). J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib50","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/1538-7445.AM2014-2624","article-title":"The novel Bruton\u2019s tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model","volume":"74","author":"Niemann","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib51","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1538-7445.AM2014-1744","article-title":"ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma","volume":"74","author":"Gardner","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.008_bib52","doi-asserted-by":"crossref","unstructured":"Rajasekaran N, Sadaram M, Hebb J, et al. Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity Blood 2014;123(12).","DOI":"10.1182\/blood.V124.21.3118.3118"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T04:28:34Z","timestamp":1600144114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0093775416000142"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.02.008","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}